Eltrombopag

Eltrombopag is an orally active small-molecule thrombopoietin receptor agonist used to increase platelet production in specific hematologic disorders. It works by stimulating the thrombopoietin receptor (c-Mpl), a receptor involved in the development and maturation of megakaryocytes—the bone marrow cells responsible for producing platelets.

Unlike naturally occurring thrombopoietin, Eltrombopag is a non-peptide molecule that interacts with the transmembrane region of the thrombopoietin receptor. This activates signaling pathways that promote megakaryocyte proliferation and platelet production. Its oral availability makes it particularly useful in treatment settings where ongoing platelet support is required.

Eltrombopag has an established role in the management of persistent or chronic immune thrombocytopenia (ITP), severe aplastic anemia, and certain cases of thrombocytopenia associated with chronic hepatitis C. Its clinical use is based on the principle of increasing endogenous platelet production rather than directly replacing platelets.

The molecule is available in different oral dosage forms and strengths, allowing treatment to be adjusted according to the indication, platelet response, age, and other patient-specific factors. Because Eltrombopag can affect platelet counts and liver function, treatment requires appropriate laboratory monitoring and dose adjustment under medical supervision.

Molecule Details

Generic Name : Eltrombopag

Active Form : Eltrombopag olamine

Drug Class : Thrombopoietin receptor agonist (TPO-RA)

Molecular Type : Non-peptide small molecule

Route of Administration : Oral

Primary Biological Target : Thrombopoietin receptor (c-Mpl)

Main Therapeutic Area : Hematology

Molecular Formula : C₂₅H₂₂N₄O₄

Molecular Weight : 442.48 g/mol

Mechanism of Action

Eltrombopag works by activating the thrombopoietin receptor on hematopoietic cells in the bone marrow.

The molecule binds to a region of the receptor that is different from the binding site used by endogenous thrombopoietin. This activates intracellular signaling pathways involved in megakaryocyte development and maturation. As megakaryocytes mature, they release platelets into the bloodstream.

This mechanism makes Eltrombopag fundamentally different from a platelet transfusion. A transfusion provides circulating platelets directly, whereas Eltrombopag encourages the patient’s bone marrow to produce more platelets.

The response is therefore dependent on the underlying condition and the patient’s remaining marrow function. This is particularly relevant in disorders such as immune thrombocytopenia and aplastic anemia, where impaired platelet production or destruction contributes to low platelet counts.

Clinical Applications

Eltrombopag has established clinical applications in several hematologic settings.

Persistent or Chronic Immune Thrombocytopenia

Eltrombopag is used in adults and children aged 1 year and older with persistent or chronic ITP when previous treatments such as corticosteroids, immunoglobulins, or splenectomy have not provided an adequate response. It is intended for patients whose thrombocytopenia and clinical condition create a meaningful risk of bleeding.

Severe Aplastic Anemia

Eltrombopag is also used in severe aplastic anemia. In the current U.S. labeling, it is indicated in combination with standard immunosuppressive therapy as first-line treatment for adults and children aged 2 years and older.

Clinical research has also investigated Eltrombopag as a treatment for patients with inadequate responses to immunosuppressive therapy and other forms of bone marrow failure.

Chronic Hepatitis C-Associated Thrombocytopenia

Eltrombopag has also been used for thrombocytopenia associated with chronic hepatitis C in situations where low platelet counts prevent initiation or continuation of interferon-based therapy.

Prescribing Information

The prescribing information provides detailed information regarding approved indications, dosing, administration, laboratory monitoring, warnings, contraindications, and clinically important drug and food interactions.

Authoritative references:

• DailyMed – Eltrombopag Prescribing Information
• FDA – Promacta Clinical Pharmacology Review
• FDA – Promacta Prescribing Information

Clinical Trial Details

Eltrombopag has been evaluated in randomized controlled studies and longer-term clinical programs across immune thrombocytopenia and bone marrow failure disorders.

One important Phase III study was the RAISE trial (NCT00370331), a randomized, double-blind, placebo-controlled study evaluating six months of Eltrombopag treatment in adults with previously treated chronic ITP. The study evaluated platelet response, safety, tolerability, and the need for rescue treatment.

Eltrombopag has also been investigated extensively in severe aplastic anemia. Clinical studies have evaluated its use alone and alongside immunosuppressive therapy, including studies examining platelet and broader blood-cell responses.

Clinical trial resources:

• ClinicalTrials.gov – Eltrombopag Clinical Studies
• RAISE Phase III Study – NCT00370331
• Eltrombopag in Severe Aplastic Anemia – NCT01623167

FDA Approval Status

Eltrombopag received its initial U.S. FDA approval in 2008. The first approval was for thrombocytopenia associated with chronic immune thrombocytopenia in patients who had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

The FDA subsequently expanded its approved uses. Eltrombopag received approval for severe aplastic anemia in 2014, and in 2018 the FDA approved its use in combination with standard immunosuppressive therapy as first-line treatment for adults and pediatric patients aged 2 years and older with severe aplastic anemia.

Current U.S. labeling includes indications for persistent or chronic ITP, chronic hepatitis C-associated thrombocytopenia in the specified treatment setting, and severe aplastic anemia.

FDA reference:

• FDA – Eltrombopag / Promacta Regulatory Information

Important Note

Eltrombopag is a prescription medicine and should be used only under appropriate medical supervision. The information on this page is intended for educational purposes and should not replace the prescribing information or individualized advice from a qualified healthcare professional.